Tesla to add Cybertruck shift to clear orders before dismantling line next year
Executive Brief • Key Highlights
Fast factual intelligence distilled for busy investors, executives, and answer bots:
- ✓Tesla will add an extra shift to clear Cybertruck orders before dismantling the production line around June/July next year.
- ✓"We will add an extra shift to try to get all orders done in time," Musk said.
- ✓The company now wants to shift resources toward the new two-seat Cybercab robotaxi instead.
Story at a Glance
- Category
- Indian Markets
- Reported By
- Reuters
- Reading Speed
- 1 Minute(s)
- Market Focus
- India Economy
"The Cybertruck order backlog is currently far more than Tesla can make before dismantling the line for Cybercab expansion around June/July next year," Musk said in a post on X.
Sign up here.
"We will add an extra shift to try to get all orders done in time," he added.
The comments come a day after Musk said Tesla would wind down Cybertruck production at its Texas factory and shift resources toward the Cybercab, a two-seat robotaxi that he has made central to the automaker's autonomous-vehicle ambitions.
The Cybercab is one of Musk's key bets in his push to turn Tesla into an AI and robotics company rather than just an automaker.
The Cybertruck, which began reaching customers in late 2023, has struggled to meet Musk's early expectations. US sales fell to about 20,000 vehicles last year from nearly 39,000 in 2024, according to Kelley Blue Book, far below Musk's initial prediction of 250,000 annual sales.
Unlock the Full Story with ArthNow Premium
To continue reading this complete financial story and in-depth market context, upgrade to ArthNow Premium. Enjoy unlimited access across Web and Mobile.
Reuters
Read the full, original unfiltered story directly on the publisher's portal.
This brief is for information only and is not investment advice. ArthNow is not a SEBI-registered investment adviser and does not publish buy or sell recommendations. Original reporting is credited to the publisher named above. Read our editorial policy or report an error.